INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uncomplicated Plasmodium Falciparum Malaria

Conditions

Uncomplicated Plasmodium Falciparum Malaria

Trial Timeline

Jan 23, 2024 → Jun 23, 2026

NCT ID

NCT05750628

About INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156

INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 is a phase 2 stage product being developed by Novartis for Uncomplicated Plasmodium Falciparum Malaria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05750628. Target conditions include Uncomplicated Plasmodium Falciparum Malaria.

What happened to similar drugs?

1 of 6 similar drugs in Uncomplicated Plasmodium Falciparum Malaria were approved

Approved (1) Terminated (0) Active (5)

✅Co-artemetherNovartisApproved

🔄KLU156 + CoartemNovartisPhase 3

🔄Broncho-munal® + PlaceboSandoz GroupPhase 3

🔄Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mgAmneal PharmaceuticalsPhase 3

🔄solithromycin + ceftriaxone + azithromycinAllergy TherapeuticsPhase 3

🔄Sulopenem-Etzadroxil/Probenecid + CiprofloxacinIterum TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05750628	Phase 2	Recruiting	Jan 23, 2024	Jun 23, 2026	Uncomplicated Plasmodium Falciparum Malaria

Competing Products

13 competing products in Uncomplicated Plasmodium Falciparum Malaria

See all competitors

Product	Company	Stage	Hype Score
ZY19489 + Ferroquine (FQ) + Placebo	Zydus Lifesciences	Phase 1	36
KLU156 + Coartem	Novartis	Phase 3	40
Artemether-lumefantrine (COA566)	Novartis	Phase 2/3	38
INE963	Novartis	Phase 2	35
KAE609 + SoC (Coartem) + KLU156	Novartis	Phase 2	35
KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation	Novartis	Phase 2	35
KAF156 + LUM-SDF + Coartem	Novartis	Phase 2	35
Co-artemether	Novartis	Approved	43
Broncho-munal® + Placebo	Sandoz Group	Phase 3	37
Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mg	Amneal Pharmaceuticals	Phase 3	37
Peramivir + Placebo	BioCryst Pharmaceuticals	Phase 2	29
solithromycin + ceftriaxone + azithromycin	Allergy Therapeutics	Phase 3	34
Sulopenem-Etzadroxil/Probenecid + Ciprofloxacin	Iterum Therapeutics	Phase 3	30